• SIGN IN
  • GET HELP
  •  

    Home Study Details


    Program Type

    Home Study Webcast

    Credits

    1 Contact Hour(s)

    Release Date

    Thursday, October 31, 2019

    Offline Date

    Saturday, April 30, 2022

    ACPE Expiration Date

    Monday, October 31, 2022

    Target Audience

    Pharmacist, Nurse

    Cost

    $4.00

    • Overview

      Unique challenges exist when managing older adults with cancer – specifically, associations between cancer and age-related physiologic changes which have a direct impact on pharmacokinetics and pharmacodynamics of cancer therapies. These challenges can affect drug dosing, dose intensity, efficacy, safety and quality of life however the breadth and depth of these issues have not been fully evaluated because the majority of clinical trials have focused on a younger and healthier population. As a consequence, there is a substantial lack of information to support clinicians to make evidence-based decisions regarding treatment with cancer therapies in older adults, especially those over age 75. Broadening trials to capture chronologic age and also functional age would allow clinicians to identify subsets of older adults who benefit from treatment versus those most vulnerable to morbidity and/or mortality. Pharmacists, nurses and allied health providers should be aware of this concept given the expansive implications on treatment-related effects.

      Handouts

      • Slide Document :   ce_3_slides.pdf

      Financial Support By

      PharmCon
    • Pharmacist

      Describe factors associated with under-enrollment of older adults in cancer trials and its impact on treatment decisions
      Describe validated tools used to screen for ‘inappropriate’ polypharmacy and to identify chemotherapy toxicity risk in older adults
      Identify the latest recommendations to improve the generation of evidence for treating older adults
      Recognize how age-related physiologic changes and functional age can influence the pharmacology of cancer treatments

      Nurse

      Describe validated tools used to screen for ‘inappropriate’ polypharmacy and to identify chemotherapy toxicity risk in older adults
      Describe factors associated with under-enrollment of older adults in cancer trials and its impact on treatment decisions
      Recognize how age-related physiologic changes and functional age can influence the pharmacology of cancer treatments
      Identify the latest recommendations to improve the generation of evidence for treating older adults
    • Activity Type

      Knowledge

      CE Broker

      20-747234

      Universal Activity Number

      Pharmacist 0798-0000-19-185-H01-P
      Nurse 0798-0000-19-185-H01-N

      ACPE PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      PharmCon is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

      In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.

    • Faculty

      Ginah  Nightingale, PharmD, BCOP
      Associate Professor, Department of Pharmacy Practice, Jefferson College of Pharmacy, Thomas Jefferson University

    HARDWARE REQUIREMENTS
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
     


    SOFTWARE REQUIREMENTS
    Microsoft Edge
    Internet Explorer 8.0 or higher
    Google Chrome
    Safari
    Firefox 3.0.3 or higher


    NETWORK REQUIREMENTS
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
     
     

    This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).